Genetic Signatures Limited (ASX:GSS)

Market Cap	31.80M -74.1%
Revenue (ttm)	19.94M +6.8%
Net Income	-11.27M
EPS	-0.05
Shares Out	227.14M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,448,551
Average Volume	1,230,469
Open	0.1600
Previous Close	0.1550
Day's Range	0.1300 - 0.1600
52-Week Range	0.0700 - 0.6900
Beta	0.52
RSI	55.78
Earnings Date	May 27, 2026

About Genetic Signatures

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: GSS

Financial Performance

In fiscal year 2025, Genetic Signatures's revenue was 19.75 million, an increase of 43.47% compared to the previous year's 13.77 million. Losses were -20.10 million, 12.6% more than in 2024.